Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Double-blind, randomised, placebo-controlled phase I trial with single-ascending and
multiple-ascending dose to evaluate safety and pharmacokinetics of oral
controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to immediate-release
nicotinamide and placebo in healthy subjects and in patients with inflammatory bowel
diseases.